News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Alistair Ring

Articles by Alistair Ring

21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer

BySara A. Hurvitz, MD,Michal Jarzab,Montserrat Munoz Mateu,Erin Cobain,Jin Zhang,Arielle Medford,Alistair Ring,Priyanka Sharma, MD,Christian Schem, MD,Ionut Temciuc,Zheng Li,Juan Pablo Zarate,Denise A. Yardley, MD

June 26th 2025

50 Pooled Exploratory Analysis of Survival in Patients (pts) With HR+/ HER2− Advanced Breast Cancer (ABC) and Visceral Metastases (mets) Treated With Ribociclib (RIB) + Endocrine Therapy (ET) in the MONALEESA (ML) Trials

ByDenise A. Yardley, MD,Yoon Sim Yap,Hamdy Abdel Azim,Richard De Boer,Mario Campone,Alistair Ring,Michelino De Laurentiis,Joyce A. O’Shaughnessy,Javier Cortes,Yogesh Chattar,Astrid Thuerigen,Juan Pablo Zarate,Liz Santarsiero

April 27th 2023

Latest Updated Articles

21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer
Published: June 26th 2025 | Updated:

Trending on CancerNetwork

FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma

FDA Approves Revumenib in R/R NPM1-Mutant AML

Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment

FDA Grants Fast Track Designation to MT-125 in Glioblastoma

HDP-101 Receives FDA Fast Track Designation in Multiple Myeloma

© 2025 MJH Life Sciences^®

All rights reserved.